Rehovot, Israel
June 4, 2013

Evogene Ltd. (“Evogene”) (TASE: EVGN) today announced plans to conduct a registered public offering of its ordinary shares in the United States. The offering is expected to commence, subject to market conditions, after the U.S. Securities and Exchange Commission completes its review process initiated by Evogene’s confidential submission of a draft registration statement. However, there can be no assurances with regard to the timing or the completion of the offering.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

Website: http://www.evogene.com

Published: June 4, 2013